SARS-CoV-2 self-amplifying mRNA vaccine(Abnova)

N/A

Report date: 2025/12/18 17:47:00

Base Information

Drug NameSARS-CoV-2 self-amplifying mRNA vaccine(Abnova)

Drug Alias NameSARS-CoV-2 SAM vaccine (Abnova)self-amplifying mRNA vaccine encoding alphaviral replicase and RBD (Abnova)

ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > self-amplifying RNA vaccine > self-amplifying mRNA vaccine

Mechanisms of ActionCoronavirus spike glycoprotein modulators

TargetsCoronavirus spike glycoprotein

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAbnova (Taiwan) Corp

China Registration ClassN/A

Develop Information

Active CompaniesAbnova (Taiwan) Corp

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A